Type 2 Diabetes Mellitus Completed Phase 4 Trials for Metformin (DB00331)

Also known as: Diabetes Mellitus Non-insulin-dependent / Type-2 Diabetes Mellitus / Diabetes Mellitus Type 2 (T2DM) / Diabetes Mellitus Type-2 / Type 2 Diabetes (T2DM) / Diabetes, Type 2 / Diabetes Mellitus, Type 2 (T2DM) / Diabetes Mellitus,Type 2 / Diabetes Type II / Type-II Diabetes Mellitus / Diabetes Mellitus 2 Type / T2DM / Diabetes Mellitus Type II / Type II Diabetes / Diabetes Mellitus, Type 2 / Type 2 Diabetes Mellitus (T2DM) / Diabetes Type Two / Diabetes Mellitus - Type 2 / Diabetes, Type II / Non-Insulin-Dependent Diabetes Mellitus / Diabetes Mellitus. Type 2 / Diabetes Type 2 / Type 2 Diabetes Mellitus (T2D) / Type 2 Diabetes (T2D) / Type II; Diabetes / Type II Diabetes Mellitus / Diabetes Mellitus, Type II / NIDDM / Type-2 Diabetes / Type 2 Diabetes Mellitus(T2DM) / Type 2 Diabetes / Type 2-diabetes / Noninsulin Dependent Diabetes Mellitus, Type II / Diabetes Mellitus Type 2 / Type Two Diabetes Mellitus / T2DM (Type 2 Diabetes Mellitus) / Type-2-diabetes Mellitus / Diabetes mellitus -adult onset / Diabetes mellitus non insulin-dep / Maturity onset diabetes / Diabetes mellitus maturity onset

IndicationStatusPhase
DBCOND0029752 (Type 2 Diabetes Mellitus)Completed4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT0031865624-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 DiabetesTreatment
NCT02014740Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 DiabetesTreatment
NCT02188186Therapeutic Efficacy of Triple Combination in Drug-naïve Korean Type 2 Diabetic PatientsTreatment
NCT01729156Effects of Metformin on Hepatic FFA MetabolismBasic Science
NCT01775813The Health Influences of Puberty (HIP) StudyPrevention
NCT01524705FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)Treatment
NCT01518101Vildagliptin Versus Liraglutide - Patient Preference After Receiving Both MedicationsTreatment
NCT00513630Study on the Prognosis and Effect of Anti-diabetic Drugs on Type-2 Diabetes Mellitus With Coronary Artery DiseaseTreatment
NCT00653302Phenotype Evaluation in Insulin Naive Patients Using Lantus (Insulin Glargine)Treatment
NCT00657943The Copenhagen Insulin and Metformin Therapy TrialTreatment
NCT00815399Pioglitazone Versus Metformin in Type 2 DiabetesTreatment
NCT00857870Insulin Glargine First Line vs Metformin in Type 2 Diabetic SubjectsTreatment
NCT00934570Activity and Metformin Intervention in Obese AdolescentsPrevention
NCT00951899The Effect of Welchol on Glucose Metabolism in Type 2 DiabeticsBasic Science
NCT01087567INSPIRE Diabetes Study: Basal Bolus Insulin as Primary Treatment of Type 2 DiabetesTreatment
NCT01509001Study of Metabolic and Haemodynamic Effects of Metformin and Glimepiride in Patients With Type 2 Diabetes MellitusTreatment
NCT01541956Efficacy of VIldagliptin aS an Add-on Therapy to Metformin Compared to Metformin Up-TitratION in Chinese Patients With Type 2 Diabetes.(VISION)Treatment
NCT01757587Galvus (Vildagliptin) vs Placebo in Combination With Metformin and InsulinTreatment
NCT01845831Sitagliptin Therapy in Hospitalized Patients With Type 2 DiabetesTreatment
NCT02007278Glycemic Excursions in Type 2 Diabetic Patients With Vildagliptin and Metformin Versus Vildagliptin and GlimepirideTreatment
NCT02050074The Role of Metformin and Colesevelam in Human GLP-1 SecretionBasic Science
NCT02526615Effects of Rosiglitazone and Metformin on Metabolism in Type 2 DiabetesTreatment
NCT01528254VERIFY:A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes MellitusTreatment
NCT02853630A Clinical Trial to Study the Effects of Two Drugs, Vildagliptin and Metformin in Patients With Type 2 Diabetes MellitusTreatment
NCT02049814Efficacy and Safety of Voglibose Compared With Acarbose in Participants With Type 2 DiabetesTreatment
NCT03202563Trial to Evaluate the Efficacy on Glycemic Variability and Safety of Gemigliptin Compared With Dapagliflozin Added on Metformin Alone or Diabetes Medication Naïve Patient in Type 2 Diabetes Mellitus (Stable II Study)Treatment
NCT02561130Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With ForxigaTreatment
NCT02954692A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in TurkeyTreatment
NCT00993187Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)Treatment
NCT01404676The Effect of Vildagliptin Based Treatment Versus Sulfonylurea on Glycemic Variability, Oxidative Stress, GLP-1, and Endothelial Function in Patients With Type 2 DiabetesTreatment
NCT01709305A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)Treatment
NCT01864174Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 DiabetesTreatment
NCT01196546Efficacy and Safety of Combination Therapy of Vildagliptin/Metformin in Patients in Type 2 Diabetes Mellitus (T2DM)Treatment
NCT00121966South Danish Diabetes Study: Evaluation of the Antidiabetic Treatment of Type 2 Diabetes MellitusTreatment
NCT00358124Insulin Glargine v Rosiglitazone as add-on Therapy in Patients Failing Sulfonylurea and Metformin Combination TherapyTreatment
NCT00367055Rosiglitazone-Metformin Combination Versus Metformin-Sulfonylurea Combination On Beta-Cell Function In Type 2 DiabetesTreatment
NCT00373178Metabolic Effects of Treatment in Patients With Recently Diagnosed Type 2 DiabetesTreatment
NCT00474838Study To Evaluate Beta Cell Function and Glycemic Outcome by Intensive Insulin TherapyTreatment
NCT00562172Insulin Glargine (Lantus) vs Sulfonylurea (SU) for BETA Cell Function (BETA Study)Treatment
NCT00612144Study Comparing Efficacy and Safety of Amaryl M and Metformin Uptitraion to Type 2 DMTreatment
NCT00708578Optimal Oral Hypoglycaemic Agents (OHA) for Combination With Insulin Glargine (Sulfonylurea vs. Metformin)Treatment
NCT00778622Body Weight Effects on Glucophage's Efficacy in Chinese Diagnosed T2DM PatientsTreatment
NCT00913367Efficacy/Safety Study of Amaryl®M 1/500 mg Twice Daily Versus Amaryl® 4 mg Both in Combination With Lantus® in Type 2 Diabetes MellitusTreatment
NCT00942318Efficacy of Continuous Subcutaneous Insulin Infusion Versus Basal-bolus Multiple Daily Injections Regimen in Type 2 DiabetesTreatment
NCT00941161Effect of Oral Combination Therapy in a Single Dosage Form in Patients With Type 2 Diabetes MellitusTreatment
NCT00975065Galvus on Met Phase 4 Study : Study to Evaluate the Efficacy and Safety of Early Combination of Vildagliptin and Metformin in Patients With Type 2 Diabetes MellitusTreatment
NCT01006590Efficacy and Tolerability of Saxagliptin add-on Compared to Uptitration of Metformin in Patients With Type 2 DiabetesTreatment
NCT01181674Remission Evaluation of Metabolic Interventions in Type 2 Diabetes (REMIT Pilot Trial)Treatment
NCT01269996JanUmet Before Insulin Lantus In Eastern Population Evaluation Program (JUBILEE) In Type 2 Diabetic PatientsTreatment
NCT01444248Compare the Compliance of Patients Treated With Once-daily (od) or Twice-daily (Bid) Glimepiride and Metformin Fixed Combination TherapyTreatment
NCT01589445Efficacy Study of Pioglitazone and Metformin and Association Between Pioglitazone Response and Peroxisome Proliferator-activated Receptor Gamma Gene Variants in Bangladeshi Type 2 Diabetes Mellitus SubjectsTreatment
NCT01604213Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetics With Coronary Artery DiseaseTreatment
NCT01758380Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During RamadanTreatment
NCT01890629Effects of Gemigliptin Versus Sitagliptin or Glimepiride With Metformin on Glucose Variability(MAGE, Glucose SD) Patients With Type 2 DM(STABLE Study)Treatment
NCT02920801Study About Effect of Saxagliptin on Circulating Endothelial Progenitor Cells and Endothelial Function in Newly Diagnosed Type 2 Diabetic PatientsTreatment
NCT01131182Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263)Treatment
NCT02002221Study of Efficacy and Safety of Vildagliptin as add-on Insulin Therapy in T2DM PatientsTreatment
NCT01766778Early add-on Vildagliptin in Patients With Type 2 Diabetes Inadequately Controlled by MetforminTreatment
NCT02836704Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)Treatment
NCT02694263Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During RamadanTreatment
NCT03267576An Efficacy Study of Canagliflozin or Sitagliptin to Determine Glucose Variability in Mexican Participants With Type 2 Diabetes Mellitus Inadequately Controlled on MetforminTreatment
NCT02167620Metformin in Co-morbid Diabetes or Prediabetes and Serious Mental IllnessTreatment
NCT00679939Study In Postmenopausal Women With Type 2 Diabetes Looking At Approved Diabetes Drugs And How They Affect Bone HealthTreatment
NCT01966978The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE StudyTreatment
NCT00241605AVANDAMET Versus Metformin For Type 2 Diabetes MellitusTreatment
NCT01842620OXEMET™ 1000 mg Coated Tablets (Metformin Hydrochloride) Bioequivalence Study. OXEMET (TM) is a Trademark of the GlaxoSmithKline Group of Companies. GLAFORNIL(TM) is a Trademark of Merck.Other
NCT03361878Pharmacokinetics of Metformin IntoleranceBasic Science
NCT00780715Response To Oral Agents in Diabetes (ROAD)- Pilot StudyTreatment
NCT01208012Impact of Liraglutide on Endothelial Function and Microvascular Blood Flow in Type 2 Diabetes MellitusTreatment
NCT00469092Comparison of Biphasic Insulin Aspart 30 Versus Insulin Glargine Both in Combination With Metformin and Glimepiride in Subjects With Type 2 DiabetesTreatment
NCT00463502The Effect of Metformin Treatment on Thyroid Hormone Metabolism in Euthyroid Patients With Type 2 Diabetes Mellitus
NCT00624364Efficacy and Safety of Biphasic Insulin Aspart 30 With Metformin in Type 2 DiabetesTreatment
NCT00491725Efficacy and Safety of Repaglinide and Metformin Combination Therapy in Type 2 Diabetes Failing on Oral Anti-diabetic DrugsTreatment
NCT00360698Insulin Glulisine in Type 2 Diabetic PatientsTreatment
NCT00386100A Type 2 Diabetes Study of the Longer-Term Glycemic Effect of AVANDAMET vs. MetforminTreatment
NCT01204580ADIponectin and Asymmetric Dimethylarginine (ADMA) Level in Type-2 Diabetes Patients After 12 Weeks of Treatment With GlimepiRide And Metformin Fixed Dose CombinationTreatment
NCT01341717Effects of Sitagliptin on Type 2 Diabetes Mellitus Patients on Treatment With Metformin and InsulinTreatment
NCT01474018QR-Bromocriptine as an Adjunct to Insulin and Metformin in the Treatment of Type 2 DiabetesTreatment
NCT01973231Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 DiabetesTreatment
NCT01438814Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic ControlTreatment
NCT01917656Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 DiabetesTreatment
NCT00819741Comparison of the Blood Sugar Lowering Effect Between Repaglinide Plus Metformin and Repaglinide Alone in Type 2 Diabetics Not Previously Treated With Oral Sugar-lowering DrugsTreatment
NCT01123980Comparison of the Blood Sugar Lowering Effect of Biphasic Insulin Aspart 30 and Insulin Glargine Both Combined With Metformin and Glimepiride in Chinese and Japanese Subjects With Type 2 Diabetes New to Insulin TreatmentTreatment
NCT01512979Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 DiabetesTreatment
NCT01519674Treatment Intensification With Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Inadequately Controlled on Sitagliptin and MetforminTreatment
NCT01144728Initiation and Titration of AmarylTreatment
NCT00619697Efficacy and Safety of Biphasic Insulin Aspart 30 in Combination With Metformin in Type 2 DiabetesTreatment
NCT02008682The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 DiabetesTreatment
NCT01595789The Effect of Liraglutide on the Treatment of Coronary Artery Disease and Type 2 DiabetesTreatment
NCT01465152Comparison of Metformin, Repaglinide or the Combination of Both in Subjects With Type 2 DiabetesTreatment
NCT00568984Efficacy and Safety of Repaglinide and Metformin Combined in Type 2 DiabetesTreatment
NCT00592969Efficacy and Safety of Metformin Plus Biphasic Insulin Aspart 30 in Type 2 DiabetesTreatment
NCT00184626Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.Treatment
NCT01720290Comparison of Repaglinide and Metformin Administered Alone or in Combination in Type 2 DiabetesTreatment
NCT00669864Effect of Biphasic Insulin Aspart 30 Combined With Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes Inadequately Controlled With Basal InsulinTreatment
NCT00807092Comparing the Efficacy and Safety of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30 on Blood Sugar Control in Subjects With Type 2 DiabetesTreatment
NCT00964184Phenotypic and Genetic Correlates of Diabetes (Non-Type 1) in Young Non-Obese Asian Indians in North India and A Study to Evaluate the Efficacy of Sitagliptin (DPP-4 Inhibitor) in a Sub-group of the Study PopulationTreatment
NCT00751114Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-naive PatientsTreatment
NCT02027753Efficacy and Safety of Insulin Glargine in Patients With Type 2 Diabetes With Inadequate Control on DPP-4 Inhibitor TherapyTreatment
NCT02040246Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New Onset Type 2 Diabetes Mellitus in ChinaTreatment
NCT01582243Safety and Efficacy of Vildagliptin Plus Metformin (SPC) Treatment in Type 2 Diabetes Mellitus PatientsTreatment
NCT02099838Effectiveness and Safety of Adding Compound Preparation of Pioglitazone and Metformin for Type 2 Diabetic PatientsTreatment
NCT00347100Insulin Glargine in Type 2 Diabetic PatientsTreatment
NCT00191464Long-Term Effects of Insulin Plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients With Type 2 DiabetesTreatment
NCT01068652Effect of Different Insulin Administrations, All in Combination With Metformin, on Glycaemic Control in Subjects With Type 2 Diabetes Inadequately Controlled by Oral Anti-diabetic DrugsTreatment
NCT00118950Effect of Metformin Versus Repaglinide Treatment in Non-Obese Type 2 Diabetic Patients Uncontrolled by DietTreatment
NCT00118963Effect of Repaglinide Versus Metformin Treatment in Non-Obese Patients With Type-2-DiabetesTreatment
NCT01117350Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents FailureTreatment
NCT01278160Comparison of Biphasic Insulin Aspart 30 Twice Daily With Two Different Initial Dosage Split Regimens in Subjects With Type 2 Diabetes: An Extension to Trial BIASP-3756Treatment
NCT02252965Metformin Extended Release Versus Metformin Immediate Release in Subjects With Type 2 DiabetesTreatment
NCT03179254Type 2 Diabetes and Ambulatory Surgery PatientsPrevention
NCT02429258Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or InsulinTreatment
NCT01972724Efficacy of Pioglitazone in Participants With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral TherapyTreatment